Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04925193
Recruitment Status : Recruiting
First Posted : June 14, 2021
Last Update Posted : January 12, 2022
Sponsor:
Collaborators:
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:

Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by physician's choice and compared prospectively to ex vivo drug sensitivity testing results. Participants will be enrolled and assigned into one of the following treatment arms:

Arm 1: Selinexor + pomalidomide + dexamethasone (SPd)

Arm 2: Selinexor + daratumumab + dexamethasone (SDd)

Arm 3: Selinexor + carfilzomib + dexamethasone (SKd)


Condition or disease Intervention/treatment Phase
Multiple Myeloma in Relapse Drug: Selinexor Drug: Pomalidomide Drug: Daratumumab Drug: Carfilzomib Drug: Dexamethasone Phase 2

Detailed Description:

This study is a single institution, open-label phase II study to evaluate the overall response rate achieved with selinexor and dexamethasone based three drug combination therapy, selected by physician's choice, in patients with relapsed/refractory multiple myeloma.

Patients with RRMM will be eligible for enrollment. During screening, in addition to standard of care disease assessments, participant's bone marrow aspirate will be evaluated using a novel ex vivo Myeloma Drug Sensitivity Testing platform (My-DST). The following agents will be eligible for physician's choice, and in parallel evaluated for sample sensitivity in MyDST: pomalidomide, carfilzomib and daratumumab. Agents will be tested individually, in combination with selinexor and in combination with selinexor and dexamethasone. Results from MyDST will be not be available to investigators at time of treatment assignment, but will be evaluated to better characterize test performance and relationship with treatment outcomes.

Investigators will assign patients to one of the following treatment combinations: Selinexor/Pomalidomide/Dexamethsone (SPd), Selinexor/Daratumumab/Dexamethasone (SDd) or Selinexor/Carfilzomib/Dexamethasone (SKd). Investigators will use patient specific considerations such as prior therapeutic exposures, response to / tolerance of prior therapies and comorbid conditions which may increase risk for toxicity with specific agents to guide expert judgement in selecting partner agent for selinexor and dexamethasone. Treatment will continue until progression of disease, unacceptable toxicity or death.

This study will evaluate if physician's choice partner drug selection for selinexor based combination therapy in RRMM will lead to an overall response rate of 75% or higher.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Actual Study Start Date : November 18, 2021
Estimated Primary Completion Date : November 2024
Estimated Study Completion Date : November 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Selinexor

Arm Intervention/treatment
Experimental: Arm 1 SPd
  • Selinexor 60 mg PO days 1, 8, 15
  • Pomalidomide 4 mg PO on days 1-21
  • Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22
  • 28 day treatment cycles
Drug: Selinexor
Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).

Drug: Pomalidomide
Oral Table

Drug: Dexamethasone
Oral tablet or injection

Experimental: Arm 2 SDd
  • Selinexor 80 mg PO days 1, 8, 15
  • Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles >6
  • Dexamethasone 40 mg PO or IV days 1, 8, 15, 22
  • 28 day treatment cycle
Drug: Selinexor
Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).

Drug: Daratumumab
Injection

Drug: Dexamethasone
Oral tablet or injection

Experimental: Arm 3 SKd
  • Selinexor 80 mg PO days 1, 8, 15
  • Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15.
  • Dexamethasone 40 mg IV or PO days 1, 8, 15, 22
  • 28 day treatment cycle
Drug: Selinexor
Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).

Drug: Carfilzomib
Injection

Drug: Dexamethasone
Oral tablet or injection




Primary Outcome Measures :
  1. Overall Response rate [ Time Frame: Two years ]
    To evaluate the overall response rate achieved with physician's choice selinexor-based combination therapy as measured by International Myeloma Working Group criteria (based on Kumar et al 2016)


Secondary Outcome Measures :
  1. MRD negative response rate [ Time Frame: 2 years ]
    To evaluate the minimal residual disease negative response rate achieved with physician's choice selinexor-based combination therapy assessed via NGS or multiparametric flow cytometry with sensitivity of 10-5.

  2. Progression Free Survival [ Time Frame: 2 years ]
    To evaluate the duration of progression free survival achieved with physician's choice selinexor-based combination therapy

  3. Overall Survival [ Time Frame: 2 years ]
    To evaluate the duration of overall survival achieved with physician's choice selinexor-based combination therapy

  4. Duration of Response [ Time Frame: 2 years ]
    To evaluate the duration of response achieved with physician's choice selinexor-based combination therapy

  5. Time to Next Treatment [ Time Frame: 2 years ]
    To evaluate the time to next treatment achieved with physician's choice selinexor-based combination therapy

  6. Safety and tolerability of selinexor [ Time Frame: 2 years ]
    To evaluate safety and tolerability of selinexor in combination with partner backbone agents using occurrence, nature and severity of Adverse Events


Other Outcome Measures:
  1. Reliability of My-DST testing to inform treatment choice [ Time Frame: 2 years ]
    Rate of assay failure

  2. Feasibility of My-DST testing to inform treatment choice [ Time Frame: 2 years ]
    Rate of identification of preferred partner therapy or combination

  3. Evaluation of My-DST related predictors of response [ Time Frame: 2 years ]
    ORR in patients with concordance or discordance between My-DST results and physicians selected regimen



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of ≤ 2
  4. Histologically confirmed diagnosis, measurable disease and evidence of disease progression of MM after 1 or more prior lines of therapy with either of the following:

    1. Documented evidence of PD after achieving at least SD for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM)
    2. ≤ 25% response (i.e, patient never achieved ≥ MR) or PD during or within 60 days from end of the most recent MM regimen (i.e., refractory MM)
  5. Patients must have measurable disease as defined by at least one of the following:

    1. Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative IgA
    2. Urinary M-protein excretion at least 200 mg/24 hours
    3. Serum FLC ≥ 10 mg/dL, provided that FLC ratio is abnormal
    4. If no measurable disease by serum or urine, then the presence of a plasmacytoma of ≥2cm in one dimension prior to start of study can be used to follow response via radiologic imaging.
  6. Adequate hepatic function:

    1. Total bilirubin < 1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 × ULN), and
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to <2.5 × ULN.
  7. Adequate renal function as determined by serum creatinine of ≤2 mg/dL OR estimated creatinine clearance of ≥ 20 mL/min, calculated using the Cockcroft and Gault formula (140 - Age) • Mass (kg)/ (72 • creatinine mg/dL); multiply by 0.85 if female (Cockcroft 1976).
  8. Adequate hematopoietic function within 7 days prior to C1D1: absolute neutrophil count ≥1000/mm3, hemoglobin ≥8 g/dL and platelet count ≥100,000/mm3 (patients for whom <50% of bone marrow nucleated cells are plasma cells) or ≥50,000/mm3 (patients for whom ≥50% of bone marrow nucleated cells are plasma cells).

    1. Patients may receive hematopoietic growth factor support, including erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (eg, eltrombopag, romiplostim, or interleukin-11) at any time.
    2. Patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study.
  9. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment.

Exclusion Criteria:

  1. Has received selinexor or another SINE (Specific Inhibitor of Nuclear Export) compound in a previous line of therapy.
  2. Has any concurrent medical condition or disease (eg, uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures.
  3. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.
  4. Known intolerance, hypersensitivity, or contraindication to study drugs.
  5. Pregnant or breastfeeding females.
  6. Major surgery within 4 weeks prior to C1D1.
  7. Active, unstable cardiovascular function, as indicated by the presence of:

    1. Symptomatic ischemia, or
    2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or
    3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction <40%, or
    4. Myocardial infarction within 3 months prior to C1D1.
  8. Subjects with active hepatitis B virus (Hep B) are allowed if antiviral therapy for hepatitis B has been given for >8 weeks and viral load is <100 IU/ml prior to first dose of trial treatment. Subjects with untreated hepatitis C virus (HCV) are allowed. Subjects with Human Immunodeficiency Virus (HIV) who have CD4+ T-cell counts ≥ 350 cells/µL and no history of AIDS-defining opportunistic infections in the last year are allowed.
  9. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment, including prior gastric bypass or bowel resection procedures.
  10. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).
  11. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.
  12. Contraindication to any of the required concomitant drugs or supportive treatments.
  13. Patients unwilling or unable to comply with the protocol, including providing 24-hour urine samples for urine protein electrophoresis at the required time points.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04925193


Contacts
Layout table for location contacts
Contact: Derek Schatz 720-848-0628 derek.schatz@cuanschutz.edu

Locations
Layout table for location information
United States, Colorado
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Derek Schatz    720-848-0628    derek.schatz@cuanschutz.edu   
Principal Investigator: Peter Forsberg         
Sponsors and Collaborators
University of Colorado, Denver
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT04925193    
Other Study ID Numbers: 20-2202.cc
P30CA046934 ( U.S. NIH Grant/Contract )
First Posted: June 14, 2021    Key Record Dates
Last Update Posted: January 12, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Daratumumab
Pomalidomide
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunologic Factors
Angiogenesis Inhibitors